Dietary therapy involving the Crohn's disease exclusion diet (CDED) is an evolving strategy
to target the microbiome and innate immunity in order to reduce inflammation and promote
healing.
The goal of the current pilot study is to evaluate the added benefit of treatment with
Ustekinumab combined with CDED in anti TNF exposed patients compared to treatment with
Ustekinumab alone in term of achieving remission.